XORTX Therapeutics Files April 2025 6-K Report
Ticker: XRTX · Form: 6-K · Filed: Apr 28, 2025 · CIK: 1729214
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer
TL;DR
XORTX filed its April 6-K, confirming 20-F reporting. Nothing major, just routine.
AI Summary
XORTX Therapeutics Inc. filed a Form 6-K on April 28, 2025, reporting for the month of April 2025. The filing indicates that the company is a foreign private issuer and will file its annual reports under Form 20-F. Allen Davidoff, the Chief Executive Officer, signed the report.
Why It Matters
This filing provides routine updates for investors and regulatory bodies regarding XORTX Therapeutics Inc.'s status as a foreign private issuer and its reporting schedule.
Risk Assessment
Risk Level: low — This is a routine filing that does not contain new material financial information or significant business developments.
Key Players & Entities
- XORTX Therapeutics Inc. (company) — Registrant
- Allen Davidoff (person) — Chief Executive Officer
- April 28, 2025 (date) — Filing date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to report information that the company has made or is required to make public in its home country, filed with exchanges on which it has a security listed, or distributed to its security holders.
Which form will XORTX Therapeutics Inc. use for its annual reports?
XORTX Therapeutics Inc. will file its annual reports under cover of Form 20-F.
Who signed the Form 6-K filing on behalf of XORTX Therapeutics Inc.?
Allen Davidoff, Chief Executive Officer, signed the Form 6-K filing.
What is the filing date of this Form 6-K?
The filing date of this Form 6-K is April 28, 2025.
What is the primary business of XORTX Therapeutics Inc. according to the filing?
According to the filing, XORTX Therapeutics Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 28, 2025 by Allen Davidoff regarding XORTX Therapeutics Inc. (XRTX).